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ABSTRACT 
MAPK pathway activation is frequently observed in human malignancies, including 
melanoma, and is associated with sensitivity to MEK inhibition and changes in cellular 
metabolism. Using quantitative mass spectrometry-based metabolomics, we identified in 
preclinical models 21 plasma metabolites including amino acids, propionylcarnitine, 
phosphatidylcholines and sphingomyelins that were significantly altered in two B-RAF 
mutant melanoma xenografts and that were reversed following a single dose of the potent 
and selective MEK inhibitor RO4987655. Treatment of non-tumour bearing animals and mice 
bearing the PTEN null U87MG human glioblastoma xenograft elicited plasma changes only 
in amino acids and propionylcarnitine. In patients with advanced melanoma treated with 
RO4987655, on-treatment changes of amino acids were observed in patients with disease 
progression and not in responders. In contrast, changes in phosphatidylcholines and 
sphingomyelins were observed in responders. Furthermore, pre-treatment levels of 7 lipids 
identified in the preclinical screen were statistically significantly able to predict objective 
responses to RO4987655. The RO4987655 treatment-related changes were greater than 
baseline physiological variability in non-treated individuals. This study provides evidence of a 
translational exo-metabolomic plasma readout predictive of clinical efficacy together with 
pharmacodynamic utility following treatment with a signal transduction inhibitor.  
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INTRODUCTION 
 
The MAPK cascade (the Ras/Raf/MEK/ERK pathway) is a receptor tyrosine kinase-mediated 
signaling pathway that regulates cell proliferation, cell cycle progression, and cell migration (1). The 
frequent constitutive activation of RAS and RAF proteins has been well-established in human 
malignancies (2). Mutations in the genes encoding members of the RAF protein family have been 
documented in 20% of cancers and 66% of melanomas   (2-6) . This pathway has been targeted at 
various loci and inhibitors of B-RAF, MEK and ERK have been developed (7). A number of MEK 
inhibitors such as trametinib and RO4987655 have shown activity in B-RAF and N-RAS mutant 
metastatic melanoma (8, 9). In these studies, currently utilised biomarkers including B-RAF and 
NRAS mutations but those are not completely predictive, and responses are observed in patients not 
harboring these mutations (10).  
We have previously shown that plasma metabolite markers of PI3K inhibition identified in mouse 
models were confirmed in a Phase I clinical trial of pictilisib (GDC-0941). The changes observed are 
consistent with the insulin resistance phenotype developing upon treatment with PI3K inhibitors (11). 
In the present study, we evaluated whether circulating metabolites also represent attractive 
biomarkers to assess the sensitivity and response to MEK inhibitors.  We implemented an exploratory 
screen for plasma metabolites exhibiting changes associated with MAPK modulation using a validated 
quantitative liquid chromatography-tandem mass spectrometry-based metabolomic analysis 
(Biocrates Absolute IDQ ®p180 kit). We first compared plasma samples from female athymic mice 
bearing xenografts of B-RAF mutant WM266.4 and A375 human melanoma with their non-tumor 
bearing age-matched littermates.  We next evaluated the effect of a single dose of RO4987655 on the 
plasma metabolite concentrations in treated animals compared with vehicle controls. We identified a 
metabolomics signature consistent with MAPK activation and reversed by treatment with the MEK 
inhibitor. We then evaluated this signature in U87MG glioma xenografts which are driven by loss of 
PTEN (and thus an activated PI3 kinase pathway) following treatment with the MEK inhibitor 
RO4987655.   
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We tested the hypothesis that the levels of these plasma metabolites may reflect the degree of MAPK 
pathway activation (e.g via B-RAF mutation); and that these novel biomarkers may be predictive of 
clinical outcome in addition to having pharmacodynamic utility following MEK inhibitor therapy.  We 
tested our preclinical metabolomic signature in 35 evaluable patients with relapsed, metastatic 
melanoma treated with RO4987655, at the maximal tolerated dose in a non-randomized open-label 
Phase I clinical trial (12).  We examined the effect of treatment on metabolite concentrations and the 
relationship between pre-treatment baseline levels of the metabolite biomarker candidates and 
objective response determined by RECIST criteria (12) in 35 patients. Time-of-day variation can 
impact significantly the plasma metabolome (13, 14). To assess the potential confounding impact of 
this factor on the candidate biomarkers, we studied the degree of variation of these metabolites in 35 
subjects with advanced melanoma and in 12 healthy male volunteers over 24h.  
We show that the metabolomics signature identified in the preclinical setting in the sensitive 
melanoma xenografts is recapitulated in patients and that baseline levels of 7 candidate biomarkers  
are prognostic of clinical response.   
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MATERIALS & METHODS 
In the exploratory preclinical screening studies, we compared plasma from female athymic mice 6-8 weeks 
of age inoculated subcutaneously with human WM266.4 or A375 (B-RAF mutant) melanoma cells with 
samples from their age-matched non-tumor bearing controls. Next, tumor-bearing and non tumor-bearing 
animals were randomized to receive the maximum tolerated dose of RO4987655 (6mg/kg) or 
cremaphor/methanol/water (1/1/3) vehicle. RO4987655 was provided by Chugai. We selected plasma 
metabolites that were different in tumor bearing mice compared with non-tumor bearing controls and 
changes that were reversed by addition of a single dose of the MEK inhibitor in both xenograft models. 
A metabolic signature identified from these studies was then tested in the PTEN (-/-) null U87MG human 
glioblastoma xenograft.  The signature was also tested in the Phase I clinical study with RO4987655 in 
patients with advanced metastatic melanoma. Finally we applied the MEK signature to patients with 
advanced solid tumors in a Phase I clinical study of the PI3K inhibitor pictilisib (clinicaltrials.gov identifier: 
NCT00876122)(15, 16). 
Preclinical human tumor xenograft studies 
All animal experiments were conducted in accordance with local and UK National Cancer Research 
Institute guidelines (17). WM266.4 melanoma cells (ATCC lot #3272826, 13/02/03), A375 (ATCC lot 
#61573377 07/07/2015 2015) and U87MG glioblastoma cells (ATCC lot unavailable; obtained 10/07/2008) 
were profiled and authenticated in house (2015). Cell lines were analyzed by short tandem repeat (STR) 
profiling. Polymorphic STR loci were amplified using a PCR primer set. The PCR product (each locus was 
labelled with a different fluorophore) was analysed simultaneously with size standards by using an 
automated fluorescent detection technique. The number of repeats at 7-10 different loci defines the STR 
profile and was cross-referenced with online databases to confirm authenticity. All cell lines showed 100% 
match and were mycoplasma negative.  
For pharmacodynamics and metabolomics experiments 2 million cells were injected subcutaneously 
bilaterally into the flanks of female NCr athymic mice 6- 8weeks of age, bred in-house. During the 
experiment, food pellets (Certified Rodent Diet 5002, Labdiet, Indianapolis, Indiana, USA) and water were 
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available ad libitum. Dosing of the animals was undertaken synchronously under sterile conditions in the 
same experiment when tumors were well-established and approximately 8-10 mm in diameter. A single 
dose of 6mg/kg RO4987655 was administered p.o. in cremaphor/methanol/water Control animals received 
an equivalent volume of vehicle. Blood and tumor samples were collected at the following times after drug 
administration: 2, 4, 8 and24 h (WM266.4); 2, 4 and 8 h,(A375) and 2, 8 and24 h (U87MG). Five mice were 
used for each time point per treatment. For therapy studies, 3 million cells were injected subcutaneously 
into right flanks and mice (10/group) were dosed p.o. with 6mg/kg RO4987655 or with vehicle for 12 
(WM266.4) or 16 days (A375).  
In pharmacodynamics, metabolomics and therapy studies, blood samples were collected (using sodium 
heparin as anticoagulant) and tumors were snap frozen. The blood samples were centrifuged at 13000 rpm 
for 2 min and the plasma transferred onto dry ice; the entire process from collection to storage in dry ice 
took less than 5 min per sample. Plasma and tumor samples were stored at -80oC until further analysis.  
 
Meso Scale Discovery (MSD)® assay 
Meso Scale Discovery (MSD) 96-well multispot assays were carried out according to the manufacturer's 
protocol with minor modifications. Briefly, ERK1/2 (duplex) plate was blocked (MSD blocking solution, as 
recommended by the manufacturer, plus 0.1% bovine serum albumin (BSA)) for 1 h at room temperature 
with shaking and then washed four times. Ten μg of total protein of tumour homogenates were added in 
duplicate wells and incubated overnight at 4 °C. Plates were washed as previously; then 25 μl of detection 
antibody was added and incubated at room temperature for 2 h with shaking. Plates were washed four 
times, 150 μl of read buffer was added, and the plates were analyzed on a MESO QuickPlex SQ 120. The 
two additional spots in each well coated with BSA were used to correct for the background and for any 
effects of the lysis buffer. Data shown are the mean values of left and right tumors of the pharmacodynamic 
experiments (five tumors per time point per treatment). 
 
Phase I expansion trial of RO4987655 
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Plasma samples for metabolomic analysis were obtained from 35 patients with advanced metastatic 
melanoma treated as part of an expansion Phase I study with RO4987655 (10). Patients received 8.5mg 
RO4987655 twice daily for 28 days cycles and metabolomic samples were collected pre-dose, 8 and 24h 
post-dose on day 1 and cycle 2 day 1 (day 29). Plasma was separated from blood (using sodium heparin as 
anticoagulant) following centrifugation at 1500 g for 15 min at 4oC; it was then stored at -80oC until further 
analysis. All aspects of the study were conducted in accordance with the Declaration of Helsinki and the 
International Conference on Harmonization Good Clinical Practice Guidelines. Written informed consent 
was obtained from all participants. The details of the Phase I study, the metabolomics sample collection 
and analysis of pictilisib responses have been described previously (15, 16). 
Plasma metabolomics analysis 
We carried out targeted, quantitative metabolomic analysis by electrospray ionization tandem MS using the 
AbsoluteIDQTM p180 kit (Biocrates Life Sciences AG, Innsbruck, Austria). Samples were anonymized and 
randomized and analyses were carried out on a Waters Acquity H-class UPLC coupled to Xevo TQ-S triple-
quadrupole MS/MS System (Waters Corporation, Manchester, UK). Quantification of the metabolites of the 
biological sample was achieved by reference to appropriate internal standards. The method follows the 
United States Food and Drug Administration Guidelines ‘Guidance for Industry – Bioanalytical Method 
Validation (May 2001)’, providing proof of reproducibility within a given error range.  
 
Data analysis 
The analytical process to derive metabolite concentrations was performed using MassLynx™ (Waters 
corporation Manchester UK) and the MetIDQ software package (Biocrates Life Sciences, Insbruck, Austria.) 
Multivariate analysis was performed using SIMCA v.14.1 software (MKS Umetrics AB, Sweden); to 
determine metabolite features that were differentially expressed between defined groups of mice: (1) 
WM266.4 tumor-bearing mice versus non tumor-bearing animals; (2)  Non-tumor bearing mice treated with 
vehicle or 6mg/kg RO498766 (3) RO-treated (6mg/kg) versus vehicle-treated mice bearing  WM266.4 
tumors. The same analysis was carried out in mice bearing A375 tumors. Metabolites responsible for 
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differences were identified using OPLS-DA (18) with a threshold of variable importance in the projection 
(VIP) value >0.5 and cross validation by permutation analysis carried out. To pass the exploratory pre-
clinical screen and establish the signature, a metabolite was required to be affected consistently across 
tumor-bearing mice versus controls and to show reverse changes in xenograft-bearing mice treated with a 
single dose of the MEK inhibitor. For the relevant plasma metabolites at each time point the changes 
relative to control concentration (pre-treatment or vehicle) were used to generate heat maps. We tested the 
metabolomics signature identified in melanoma mice with an additional cohort bearing PTEN null U87MG 
human glioblastoma xenografts following treatment with a single dose of the MEK inhibitor.  
In the clinical studies with the MEK inhibitor and the PI3K inhibitor, we focused on the metabolites that had 
been identified in the pre-clinical studies. Changes relative to pre-treatment baseline levels were calculated 
for each patient across all time points for each metabolite. In the study with the MEK inhibitor, the 
separation between the response categories of disease progression and objective RECIST response 
(Response Evaluation Criteria in Solid tumors) was assessed using the receiver operator characteristic 
(ROC) curve. The statistical significance of the differences were determined using Mann-Whitney, Kruskall-
Wallis and Dunn`s multiple comparison tests (Graphpad Prism v6, California, USA), and values <0.05 were 
considered statistically significantThe venn diagram was generated on 
http://bioinformatics.psb.ugent.be/webtools/Venn/ website. Clustered heatmap diagram was constructed 
using MetaboAnalyst 3.0 (19).  
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RESULTS 
Preclinical models 
RO4987655 inhibits ERK phosphorylation and tumor growth in human melanoma xenografts 
Following a single dose of 6mg/kg RO4987655 to female athymic mice bearing s.c. human B-RAF mutant 
melanoma xenografts WM266.4 or A375 a complete inhibition of ERK phosphorylation was observed in 
tumors at 2,6 and 8h post treatment in both models (Fig. 1A and B). This target modulation resulted in 
significant tumor growth inhibition following daily treatment with RO4987655 at 6mg/kg with T/C of 16% and 
3.5% respectively (Fig. 1C) .This schedule was well tolerated with no body weight loss. 
The metabolomics workflow is summarized in Fig. 2A 
Identification of the metabolomic signature 
We compared plasma samples from mice bearing WM266.4 and A375 melanomas with their non-tumor 
bearing age-matched littermates. Orthogonal partial least square-discriminant analysis (OPLS-DA) of the 
metabolic profile revealed 11 metabolites increased in these MAPK-driven tumors and decreased following 
RO4987655 treatment plus 10 metabolites decreased in the plasma of tumor bearing mice and increased 
following treatment (summarized in Fig. 2B and Fig. 2C). Hence, a total of 21 metabolites including 
propionylcarnitine, arginine, asparagine, isoleucine, leucine, phenylalanine, tryptophan, tyrosine, valine, 
methylsulfoxide, 7 phosphatidylcholines (PC aa C30:0, PC aa 36:6, PC aa 40:1, PC ae 42:0, PC ae 44:3 
and PC ae 44:6 and 4 sphingomyelins (SM 16:0, SM 20:2, SM C24:1, SM C26:1  were different in plasma 
of animals bearing B-RAF mutant melanomas compared with controls and inversely affected by treatment 
with the MEK inhibitor. (Fig. 2D). Overall, propionylcarnitine and the aminoacids were decreased in the 
plasma of tumor bearing animals compared with controls and increased by treatment. In contrast, lipids 
were increased in plasma of tumor bearing mice and decreased with treatment (Fig. 2D). In tumor bearing 
mice, the metabolic effects were most pronounced at 4 and 8h and were different from those observed in 
non-tumor bearing mice (Fig 2D). In the PTEN (-/-) null human glioblastoma xenograft (U87MG), which is 
not MAPK-dependent, a single dose of the MEK inhibitor had different effects on the plasma metabolites 
identified in melanoma models (Fig. 2D, fifth column) with only amino acids and propionylcarnitine 
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increased following treatment with the MEK inhibitor. Reversed changes of lipid levels following 
RO4987655 treatment were observed only in melanoma xenograft models. 
 
The metabolic effects following RO4987655 are different in clinical responders and patients with 
disease progression 
We examined the relationship between all 182 metabolites and objective responses determined by RECIST 
criteria (12) in 35 evaluable patients treated with 8.5 mg/kg (i.e the maximum tolerated dose) of 
RO4987655. The OPLS-DA model revealed a high degree of separation between the response categories 
of disease progression and objective RECIST response (Fig. 3A). The most significant effects were 
observed on propionylcarnitine, and aminoacids that showed an increase at all time points. The 
sphingomyelins and one phosphatidylcholine (PC aa C38:6) showed an overall decrease at 24h but this 
was not statistically significant (Table 1, Fig. 3B PD-PR-SD column). Additionally, the metabolic alterations 
were significantly different between patients with disease progression and those who achieved an objective 
response (Fig. 3B, PD and PR columns). Overall, progressors showed a significant  increase in amino acids 
relative to pre-dose levels while responders showed no significant increase in these amino acids up to 
Cycle 2, 24h. In addition, a significant decrease in 7 phospholipids was observed from cycle 2 which was 
not observed in patients who progressed.  The metabolite changes observed in responsive patients were 
consistent with the effects observed in mice bearing the sensitive WM266.4 and A375 melanoma 
xenografts and the effects in non-responsive patients were in line with the effects in non-tumour bearing 
mice or the U87MG xenograft model (Fig. 2C, Fig. 3B, Table 2). In addition, the effect of the PI3K inhibitor 
pictilisib on the MEK signature also showed an increase in the amino acids but no decrease in 
phospholipids which is comparable with that observed in patients with progressive disease following 
RO4987655 administration. The effect on amino acids following pictilisib was not observed below 80mg 
(suggesting that it is genuinely associated with PI3K inhibition and not disease progression) 
(Supplementary Figure 1).  
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Baseline levels of 7 plasma metabolites predict clinical response to RO4987655 
We examined the relationship between pre-treatment baseline levels of the metabolite biomarker 
candidates and objective response determined by RECIST criteria (12) in 35 evaluable patients. Of 21 
biomarker candidates, 7 plasma metabolites were significantly different between patients who responded 
and those who progressed (p-values <0.05) and all 7 metabolites exhibited an estimated area under the 
receiver operating characteristic curve of ≥0.75 (Table 3). The plasma levels of all these lipid metabolites 
were higher in patients who subsequently achieved an objective response to RO4987655.  (Fig.3B). In 
contrast, a poor separation between the metabolic profiles of patients harbouring B-RAF-mutant and B-RAF 
wild-type melanomas was observed with only 3 metabolites correlating with B-RAF mutational status. The 
lack of a significant difference in these plasma metabolites between the two groups is summarised in Table 
3.  
A heat map of an unsupervised analysis of the pre-treatment levels of selected lipids (based on preclinical 
signature Fig. 3C) shows clustering of 7/8 all of patients with partial response and 11/12 patients with 
progressive disease (Fig. 3C). 
Collectively, these results suggest hitherto-unknown biological pathways involving the panel of metabolite 
biomarkers being implicated in mechanisms underlying vulnerability of melanoma cells to MEK inhibition. A 
summary of the levels of 4 representative metabolites throughout the course of treatment is presented in 
Fig. 3D.   
 
Changes in the metabolite biomarkers following RO4987655 exceed time-of-day variations 
Time-of-day variation can impact significantly on the plasma metabolome (13, 14). To assess the potential 
confounding impact of this factor on the candidate biomarkers, we studied the degree of variation of these 
metabolites in an additional study (Supplementary Table 1). One study examined the variability of these 
metabolites in 35 subjects with advanced melanoma and the second evaluated time-of-day variation over a 
24-hour period using the same clinical sampling schedule in 12 healthy male volunteers. Reassuringly, 90% 
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of RO4987655-related changes (19 out of 21) of the metabolite biomarkers were greater than the variability 
observed in these physiologic/time-of-day studies.  
 
DISCUSSION  
This study provides evidence of plasma metabolites as biomarkers predictive of objective response to a 
molecularly targeted anti-cancer drug with good discrimination. The prior identification of biomarker 
candidates in molecularly-characterized preclinical tumor screens where control animals were included 
significantly increases confidence that these metabolites represent genuine exometabolomic changes 
associated with MAPK pathway modulation.  
We demonstrated that basal levels of 21 metabolites including amino acids, glycerophosphocholines and 
sphingomyelins were differentially affected in clinical responders and progressors following treatment with 
RO4987655. In patients with progressive disease, we observed an increase in amino acids and no 
decrease in lipids. This significant increase in amino acids was also observed following treatment with the 
PI3K inhibitor pictilisib where no therapeutic benefit was observed in all but one patient (15, 16). In patients 
responding to the MEK inhibitor, the amino acids and lipids were decreased. In addition, basal levels of 7 
metabolites (glycerophosphocholines and sphingomyelins) were significantly able to predict response with 
higher levels in responders.In contrast to the metabolite biomarker changes, the median decrease in ERK 
phosphorylation in tumors was higher in patients with a B-RAF mutation than those without; but there was 
no evidence of a significant difference in pERK inhibition between different response outcome groups (12). 
A previous study showed that reduction of p-ERK was correlated with response to the B-RAF inhibitor 
vemurafenib (20); however, there is published evidence that this is not the case for MEK inhibitors (12). In 
addition, the metabolic responses measured by FDG-PET confirmed the negative predictive value of FDG-
PET for MEK inhibition (10). In this context, it is notable that we observe an increase in branched chain 
amino acids in non-responders and following treatment with pictilisib which is consistent with the insulin 
resistant phenotype (16). In addition, our previous studies showed a decrease in glycerophosphocholine in 
PI3K-activated tumors and an increase following PI3K inhibition with pictilisib (16)). The fact that low levels 
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of these phospholipids are predictive of resistance to the MEK inhibitor is consistent with the PI3K activated 
metabotype. It has been shown that de novo PI3K activation is associated with resistance to MEK inhibitors 
(21) which is consistent with our metabolic findings. PI3K activation is also known to be induced as a result 
of MEK inhibition but our metabolic response to doses of drug inhibiting the MAPK pathway does not 
recapitulate that observed upon PI3K activation whatever the therapeutic outcome. Studies aiming at the 
prediction of sensitivity to MEK inhibition by gene expression profiling have also shown compensatory 
signaling through RAS effectors other than PI3K (22). Tumors often harbor genetic abnormalities in both 
PI3K and MAPK pathways as observed in WM266.4 (although they are known to be driven primarily by 
MAPK). In addition, PI3K pathway abnormalities in the patients enrolled in the clinical study have not been 
determined and melanomas have a high mutational load in addition to the known PI3K and MAPK drivers 
(23-25). Our exometabolomic data in sensitive human tumor xenograft models and clinical responders are 
in agreement with cellular metabolomics studies by NMR reporting decreased glycerophosphocholine levels 
which were associated with lowered expression of choline-kinase α following MEK inhibition (26). Increased 
levels of phosphatidylcholines ,delivered by nanoparticles, in the cellular plasma membrane is able to 
activate EGFR which is one of the major mechanisms of resistance to MEK inhibition suggesting effectors 
for these molecules upstream and downstream of MAPK (23, 27, 28). Similarly, previous studies 
established that activated sphingomyelinase leads to ceramide-mediated activation of MAPK (29). In our 
study, we show a decrease in sphingomyelins following MEK inhibition suggesting complex regulation of 
sphingomyelins on the MAPK network. 
 
We and others have demonstrated that levels of plasma metabolites vary throughout the day (12,13). 
Reassuringly, we have demonstrated that the variations observed in the biomarker metabolites following 
treatment with the MEK inhibitor exceed time-of-day variations both in patients and healthy volunteers. We 
found that over 70% (15 out of 21) of the metabolites identified pre-clinically translate to the clinical setting 
and we also found additional metabolites that could be associated with responses using the clinical data 
alone. The metabolomic profiling of plasma (as opposed to tumor tissue) circumvents significant limitations 
of many current standard biomarkers (for example lack of stability of phospho signals) and importantly is 
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readily amenable to repeated sampling.  In addition, the use of a mass spectrometry-based platform 
crucially allows for up-scaling and implementation in large studies. We emphasize, however, that this is a 
retrospective study with a limited sample size, and hence cannot be regarded as definitive at this time. 
Further investigations in an independent cohort are needed. This is challenging given the fact that MEK 
inhibitors are now administered in combination in the clinical setting. Although the mechanistic links 
between MAPK pathway modulation and the panel of plasma metabolite biomarkers are currently poorly 
understood, we anticipate that our novel findings may be helpful in guiding future investigations including 
those of MEK inhibitor resistance. 
 
In summary, using LC-MS metabolomics, we showed that plasma metabolite markers of MEK inhibition can 
be identified in mice bearing human melanoma xenografts. In patients with advanced melanoma treated 
with RO4987655, the pre-treatment levels of 7 candidate plasma metabolite biomarkers identified in the 
pre-clinical screen were statistically significantly able to retrospectively predict objective responses to 
RO4987655. Our current findings and those we reported previously (10) provide a rational study design for 
the determination of metabolomic signatures of drug sensitivity/activity and resistance which is directly 
translatable to the identification of preclinical and clinical metabolomic biomarkers for other new classes of 
drug. Thus metabolomics analysis can be added to the technical approaches to support the use of The 
Pharmacological Audit Trail for biomarker led decision making in cancer therapeutics (30)  
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Table 1: Evaluation of the significance of the changes in metabolite levels compared with pre-dose levels following treatment 
with the MEK inhibitor RO4987655. Statistical tests carried out are Kruskal-Wallis test for all time points and Dunn’s multiple 
comparison tests for individual time points. (p values <0.05 are shaded grey). Mean values are percentage increase or decrease 
relative to time 0. 
    Kruskal-Wallis   Dunn`s mutliple comparison test 
        C1-8h C1-24h C2-pre C2-8h C2-24h 
    p value   mean adj. p value mean adj. p value mean adj. p value mean adj. p value mean adj. p value 
Metabolites   
 
  
          C3   0.0016   28.46 0.0099 34.47 0.0004 24.83 0.0089 24.8 0.1847 43.53 0.0378 
Arg   < 0.0001   42.23 < 0.0001 26.88 0.0036 24.54 0.0035 35.75 0.0024 35.27 0.0001 
Asn   < 0.0001   34.09 < 0.0001 20.31 0.0008 28.25 < 0.0001 47.25 < 0.0001 35.67 < 0.0001 
Ile   < 0.0001   59.14 < 0.0001 31.88 0.0001 15 0.3326 47.95 0.0003 34.13 0.0021 
Leu   < 0.0001   47.26 < 0.0001 26.16 < 0.0001 14.79 0.0101 36.7 0.0001 26.67 0.0002 
Phe   < 0.0001   28.74 < 0.0001 13.47 0.0198 19.79 0.0051 27.75 0.0027 25.93 0.0022 
Trp   0.0371   22.57 0.1073 15.94 0.1526 5.333 > 0.9999 -0.55 > 0.9999 3.733 > 0.9999 
Tyr   0.0003   36.4 0.0004 27.56 0.0036 28.92 0.0216 35.5 0.0049 33.6 0.0015 
Val   0.0004   16.49 < 0.0001 13.41 0.0012 8.375 0.0847 11.9 0.0417 11.07 0.0206 
Met-SO   0.0046   117.8 0.0348 110.2 0.7205 355.7 0.4795 162.8 0.0286 209.9 0.0034 
PC aa C30:0   0.2272   0.6286 > 0.9999 2.156 > 0.9999 25.17 0.4472 10.55 > 0.9999 -1 > 0.9999 
PC aa C38:6   0.0005   4.286 > 0.9999 4.844 > 0.9999 -4.417 0.3513 -9.1 0.0409 -16.67 0.0068 
PC aa C40:1   0.2189   3.8 > 0.9999 6.75 > 0.9999 -0.9167 > 0.9999 -5.9 0.7959 -0.5333 > 0.9999 
PC ae C42:0   0.626   2.514 > 0.9999 5.094 > 0.9999 3.083 > 0.9999 -3.45 > 0.9999 1.467 > 0.9999 
PC ae C42:4   0.6558   0 > 0.9999 2.531 > 0.9999 9.417 > 0.9999 -5 0.416 6.267 > 0.9999 
PC ae C44:3   0.7112   4.771 > 0.9999 10.78 > 0.9999 15.17 > 0.9999 3.9 > 0.9999 9.533 > 0.9999 
PC ae C44:6   0.6457   -0.8286 > 0.9999 -1.594 > 0.9999 6.542 > 0.9999 -4.2 0.9183 0.1333 > 0.9999 
SM C16:0   0.0019   1.686 > 0.9999 2.719 > 0.9999 -1.292 0.297 -11.85 0.006 -11.6 0.0093 
SM C20:2   0.0317   3.886 > 0.9999 6.781 > 0.9999 -1.25 0.8285 -10.2 0.0484 -9.867 0.0728 
SM C24:1   0.1213   1 > 0.9999 3.344 > 0.9999 0.875 > 0.9999 -10.1 0.1824 -8.667 0.2434 
SM C26:1   0.0096   -1.057 > 0.9999 2.688 > 0.9999 0.375 > 0.9999 -13.55 0.0303 -13 0.0591 
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Table 2: Statistical analysis of the effect of treatment with RO4987655 on metabolites identified pre-clinically in patient with progressive 
disease (PD) and partial response (PR). Statistical tests carried out are Kruskal-Wallis test for all time points and Dunn’s multiple 
comparison tests for individual time points. (p values <0.05 are shaded grey). Mean values are percentage increase or decrease relative to 
Time 0. 
 PD PR 
 
Kruskal-
Wallis Dunn`s mutliple comparison test 
Kruskal-
Wallis Dunn`s mutliple comparison test 
  C1-8h C1-24h C2-pre C2-8h C2-24h  
C1-8h C1-24h C2-pre C2-8h C2-24h 
Metabolites p value mean 
Adj.P 
Value 
mean 
Adj.P 
Value 
mean 
Adj.P 
Value 
mean 
Adj.P 
Value 
mean 
Adj.P 
Value 
p 
value 
mean 
Adj.P 
Value 
mean 
Adj.P 
Value 
mean 
Adj.P 
Value 
mean 
Adj.P 
Value 
mean 
Adj.P 
Value 
C3 0.2294 29.42 0.1505 27.58 0.1348 14 0.3537 11.86 >0.9999 14.17 0.6901 0.6324 43.13 >0.9999 30 0.4572 29 >0.9999 23 >0.9999 78.2 >0.9999 
Arg 0.0043 50.33 0.0022 41.08 0.0499 35.38 0.1106 57.86 0.0048 39.17 0.0489 0.2428 22.63 0.2633 13.88 >0.9999 5.571 >0.9999 21.57 >0.9999 31 0.3115 
Asn <0.0001 47.67 <0.0001 21.25 0.0233 43.13 0.0003 62.71 0.0004 27.67 0.0476 0.1012 15.75 0.7656 15.13 0.7373 21.43 0.2235 24.86 0.6127 47 0.0185 
Ile 0.0006 69.08 0.0004 31.75 0.2091 24.25 >0.9999 80.43 0.0016 42.5 0.2167 0.0535 43.75 0.0699 33.38 0.0371 6.714 >0.9999 23.14 >0.9999 30.2 0.0826 
Leu <0.0001 60.58 <0.0001 24.67 0.2073 24.5 0.1727 71.29 0.0003 37.5 0.0635 0.0879 32 0.0759 21.5 0.1328 5.286 >0.9999 14.43 >0.9999 22.8 0.0997 
Phe 0.0007 41 0.0008 13.92 0.4929 24.75 0.048 53.14 0.0008 28.17 0.1214 0.7512 10.75 >0.9999 6.5 >0.9999 2 >0.9999 1 >0.9999 19.2 >0.9999 
Trp 0.0539 36.83 0.0142 13.33 >0.9999 21 0.195 26.71 >0.9999 5.167 >0.9999 0.0291 12 >0.9999 14.75 >0.9999 -15.57 0.6823 -31.14 0.1187 -1.8 >0.9999 
Tyr 0.0003 56.75 0.0003 31.75 0.0759 38.88 0.0124 63.29 0.0004 38.67 0.0375 0.2771 20 >0.9999 17.63 >0.9999 10.29 >0.9999 3.286 >0.9999 28.4 0.6478 
Val 0.0118 26.25 0.0013 11.08 0.2421 13.13 0.2827 26.57 0.0475 10.67 0.3723 0.148 10.5 0.837 13.38 0.0637 4 >0.9999 -0.7143 >0.9999 11 0.5475 
Met-SO 0.063 38 0.672 30.14 0.9448 34.75 >0.9999 116.7 0.0204 113.5 0.1624 0.9454 240.6 >0.9999 226.4 >0.9999 833.8 >0.9999 125 >0.9999 56.25 >0.9999 
PC aa C30:0 0.0566 19.25 0.2935 7.833 >0.9999 42.38 0.1132 46 0.2131 5 >0.9999 0.5601 -5.875 >0.9999 -5.375 >0.9999 6 >0.9999 -16.71 >0.9999 -11.4 >0.9999 
PC aa C38:6 0.0657 13.92 0.5686 9.75 >0.9999 4 >0.9999 17.86 >0.9999 -18.5 0.4409 0.0243 -2.75 >0.9999 5.75 >0.9999 -17 >0.9999 -34.86 0.1757 -28 0.4232 
PC aa C40:1 0.5102 6.583 >0.9999 6.167 >0.9999 8.25 0.8057 8.143 >0.9999 0 >0.9999 0.0234 8.375 >0.9999 13.13 >0.9999 -20 0.5132 -21.57 0.3441 -16.4 0.7246 
PC ae C42:0 0.5951 7.833 0.4055 6.667 >0.9999 7.75 0.8341 9.286 >0.9999 -1 >0.9999 0.5154 4.625 >0.9999 9.25 >0.9999 8.429 >0.9999 -11.57 >0.9999 -2.8 >0.9999 
PC ae C42:4 0.3738 11.25 0.2456 4.25 >0.9999 18.38 >0.9999 19.71 0.6419 4.667 >0.9999 0.0052 -6.5 >0.9999 0.875 >0.9999 -15.43 0.3501 -34.43 0.0038 -20.2 0.3293 
PC ae C44:3 0.7392 6.5 >0.9999 4.917 >0.9999 22.75 >0.9999 20.29 >0.9999 7.5 >0.9999 0.1296 12.25 >0.9999 24.75 0.5477 19.29 >0.9999 -11 >0.9999 -9 >0.9999 
PC ae C44:6 0.5176 8.167 >0.9999 1.25 >0.9999 13 >0.9999 20.29 0.7778 2.833 >0.9999 0.0166 -10.75 >0.9999 -3.5 >0.9999 -13.57 0.8398 -32.57 0.0074 -22.2 0.1035 
SM C16:0 0.0507 12.25 >0.9999 7.25 >0.9999 -3.75 0.5932 0.2857 0.9647 -14.33 0.2328 0.0066 -4.75 >0.9999 1.75 >0.9999 -11.57 0.4553 -24.29 0.0415 -20.8 0.0531 
SM C20:2 0.3264 16.17 >0.9999 10 >0.9999 -7.875 >0.9999 6 >0.9999 -11.33 >0.9999 0.0014 0 >0.9999 7.875 >0.9999 -16.14 0.0913 -24.86 0.0344 -25.2 0.0148 
SM C24:1 0.1562 12.75 0.5076 8.25 >0.9999 -5.5 >0.9999 0.1429 >0.9999 -11.67 >0.9999 0.0739 -7.5 >0.9999 2.5 >0.9999 -5.143 >0.9999 -19.29 0.275 -17.2 0.1544 
SM C26:1 0.0796 8.917 0.9514 6 >0.9999 -4.75 >0.9999 -4.714 >0.9999 -16.67 0.4224 0.0986 -6 >0.9999 8 >0.9999 -7.286 >0.9999 -22.14 0.3339 -19.6 0.7613 
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Table 3: Relationship between baseline candidate biomarker levels with objective response and presence of tumor BRAF-
mutation (p values <0.05 are shaded grey) 
  
Mann-
Whitney 
test 
Patient comparison 
 
ROC analysis  PD vs PR 
 
Mann-
Whitney 
test 
+/- BRAF mutation 
  
p value 
Median of PD 
(µM) 
Median of PR ( 
µM )  
AUC 
95% confidence 
interval 
p value 
 
p value 
Median of 
mutated (µM) 
Median of non 
mutated (µM) 
Metabolites 
            
C3 
 
0.6239 0.2585, n=12 0.2396, n=8 
 
0.5729 0.3121 to 0.8337 0.5892 
 
0.3114 0.2737, n=7 0.2520, n=13 
Arg 
 
0.0096 64.51, n=12 87.93, n=8 
 
0.8438 0.6646 to 1.023 0.0109 
 
> 0.9999 71.06, n=7 72.84, n=13 
Asn 
 
0.6784 43.60, n=12 43.44, n=8 
 
0.5625 0.3029 to 0.8221 0.6434 
 
0.1827 44.92, n=7 41.54, n=13 
Ile 
 
0.5714 59.99, n=12 55.37, n=8 
 
0.5833 0.3146 to 0.8521 0.5371 
 
0.3114 59.88, n=7 50.85, n=13 
Leu 
 
0.5208 107.6, n=12 101.5, n=8 
 
0.5938 0.3186 to 0.8689 0.4875 
 
0.2414 102.6, n=7 97.70, n=13 
Phe 
 
0.0979 60.29, n=12 67.46, n=8 
 
0.7292 0.5073 to 0.9510 0.0896 
 
0.0145 75.23, n=7 58.57, n=13 
Trp 
 
0.238 51.96, n=12 61.09, n=8 
 
0.6667 0.4182 to 0.9151 0.217 
 
0.588 61.58, n=7 56.64, n=13 
Tyr 
 
0.0314 51.91, n=12 66.46, n=8 
 
0.7917 0.5862 to 0.9972 0.0308 
 
0.5356 66.20, n=7 54.96, n=13 
Val 
 
> 0.9999 189.0, n=12 178.6, n=8 
 
0.5 0.2272 to 0.7728 1 
 
0.6992 185.7, n=7 187.2, n=13 
Met-SO 
 
0.3829 0.5386, n=7 0.2994, n=7 
 
0.6531 0.3293 to 0.9768 0.3379 
 
0.1469 0.2836, n=5 0.5988, n=9 
PC aa C30:0 
 
0.1349 2.829, n=12 3.952, n=8 
 
0.7083 0.4611 to 0.9556 0.1228 
 
0.7573 3.799, n=7 2.895, n=13 
PC aa C38:6 
 
0.0055 58.20, n=12 115.5, n=8 
 
0.8646 0.6647 to 1.065 0.0069 
 
0.588 100.2, n=7 65.83, n=13 
PC aa C40:1 
 
0.0159 0.3345, n=12 0.4752, n=8 
 
0.8229 0.6194 to 1.026 0.0168 
 
0.9385 0.3673, n=7 0.3495, n=13 
PC ae C42:0 
 
0.0124 0.4863, n=12 0.7681, n=8 
 
0.8333 0.6543 to 1.012 0.0136 
 
0.1146 0.7605, n=7 0.5126, n=13 
PC ae C42:4 
 
0.1569 0.6470, n=12 0.7494, n=8 
 
0.6979 0.4640 to 0.9318 0.1427 
 
0.7573 0.6656, n=7 0.7221, n=13 
PC ae C44:3 
 
0.0096 0.1298, n=12 0.1833, n=8 
 
0.8438 0.6645 to 1.023 0.0109 
 
0.1574 0.1776, n=7 0.1391, n=13 
PC ae C44:6 
 
0.1349 0.7642, n=12 1.056, n=8 
 
0.7083 0.4555 to 0.9611 0.1228 
 
0.2749 0.6329, n=7 0.8804, n=13 
SM C16:0 
 
0.1349 185.9, n=12 203.0, n=8 
 
0.7083 0.4779 to 0.9388 0.1228 
 
0.1348 197.7, n=7 190.1, n=13 
SM C20:2 
 
0.0201 0.7086, n=12 1.007, n=8 
 
0.8125 0.6207 to 1.004 0.0206 
 
0.0085 0.9905, n=7 0.7045, n=13 
SM C24:1 
 
0.1569 212.1, n=12 239.0, n=8 
 
0.6979 0.4586 to 0.9372 0.1427 
 
0.2106 234.1, n=7 216.7, n=13 
SM C26:1 
 
0.2083 0.7365, n=12 0.8440, n=8 
 
0.6771 0.4319 to 0.9223 0.1897 
 
0.0111 0.8771, n=7 0.7203, n=13 
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FIGURE LEGENDS 
Figure 1:  
(A) (B) Inhibition of ERK phosphorylation by RO4987655 in WM266.4 and A375 human melanoma xenografts 
Ratio of phosphorylated (pERK) and total ERK (tERK) demonstrates total inhibition of phosphorylation of ERK in both melanoma 
models after RO4987655 (RO) administration compared to vehicle control (VEH), measured by MSD. Values are Mean+ SEM of 
left and right tumors. 
(C) Tumor growth inhibition following daily treatment with RO4987655 in WM266.4 and A375 human melanoma xenografts. 
Target modulation resulted in significant growth inhibition following daily treatment with RO4987655 at 6mg/kg with T/C of 16 % and 
3.5 % in WM266.4 and A375 tumor bearing mice, respectively. Values are Mean+ SEM. 
Figure 2: Metabolomic analysis of plasma from tumor bearing mice or control mice treated with RO4987655 
(A) Experimental workflow.  
(B) (C) Venn diagrams showing the overlap in plasma metabolites between preclinical animal models: (A) metabolites increased in 
WM266.4 and A375 tumor bearing mice compared with non-tumor bearing age-matched controls and decrease in the tumor-
bearing mice treated with RO4987655 compared with vehicle; or vice versa (B).   
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(D) Heat map of differences between MAPK-hyperactivated tumor-bearing mice compared with age-matched non-tumor bearing 
littermates (change relative to control) and changes across 24 h in candidate plasma metabolite biomarkers following treatment 
with RO4987655 (relative to vehicle control) in tumor-bearing and non-tumor bearing mice. (aa, acyl-acyl; ae, acyl-alkyl; Cx:y, 
where x is the number of carbons in the fatty acid side chain; y is the number of double bonds in the fatty acid side chain; PC, 
phosphatidylcholine; SM, sphingomyelin.) 
Figure 3: Metabolomic profiling of RO4987655 in a Phase I clinical trial 
(A) OPLS-DA according to response to RO4987655 in patient plasma metabolomic profiles across all time course of treatment 
(Cycle 1 and Cycle 2). A total of 182 metabolites were measured.  
(B) Heat map illustrating the changes relative to baseline treatment in 21 candidate metabolite biomarkers. Data are presented 
from left to right in all patients (PD-SD-PR column), in patients with progressive disease (PD column), in partial responders (PR 
column) on Cycle 1 8h, Cycle 1 24h, Cycle 2 predose, Cycle 2 8h and Cycle 2 24h.  
(C) Heatmap of unsupervised clustering according to the pre-treatment concentrations of 20 metabolites identified as predictors of 
response (MetaboAnalyst 3.0, Pareto scaling, Distance Measure: Euclidean; Clustering Algorithm: Ward). 
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(D) Concentrations of representative plasma metabolites in patients with metastatic melanoma at baseline and following treatment 
with RO4987655. Values are Mean+ SEM in patients who achieved an objective response (n=8) (PR) or experienced disease 
progression (n=12) (PD).  
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